PDL BioPharma

Edison Investment Research is terminating coverage on PDL BioPharma. Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Previously published reports can still be accessed via our website.

Equities

Equities by Sector

Sectors

Investment Strategy

Latest

Equity strategy and market outlook – April 2024

Equity strategy and market outlook – March 2024

Equity strategy and market outlook – February 2024

Thematics

Latest

Listed private equity – Performing a balancing act

ConsumerWatch – At least someone loves me

MediaWatch – Rinse and repeat

Audiovisual

Latest

Checkit – executive interview

International Public Partnerships – executive interview

Unlocking US capital: Strategies for non-US-listed businesses

About Edison

About Edison

Careers

PDL BioPharma (US: PDLI)

Latest Insights

PDL BioPharma — Dissolution set for the year end

PDL BioPharma — Selling off Noden

PDL BioPharma — Evofem shares distributed and Phexxi approved

PDL BioPharma — Accelerating asset monetization

Sector

Financials

Research

PDL BioPharma — Investing in Evofem

PDL BioPharma — Buyback significantly reduces share count

PDL BioPharma — Q119 results

PDL BioPharma — Q318 results

PDL BioPharma — Big in Japan

PDL BioPharma — First quarter results

PDL BioPharma — A strong year

PDL BioPharma — Seeking additional commercial products

PDL BioPharma — Q1 earnings

PDL BioPharma — Building the Noden platform

PDL BioPharma — Update 8 December 2016

PDL BioPharma — Update 11 August 2016

PDL BioPharma — Update 15 July 2016

PDL BioPharma — Update 2 June 2016

PDL BioPharma — Update 12 May 2016

PDL BioPharma — Update 3 March 2016

PDL BioPharma — Update 17 November 2015

Machine learning in drug development

Outlook for 2023: Biotechs remain central to novel drug development

Oncology ABCs (part four): Blood cancers (AML) – notable innovations

Cell and gene therapies

Drug delivery platforms

Oncology ABCs (part three) – thinking outside the box in women’s cancer

Neuroscience comeback

IPO apocalypse

Oncology ABCs (part two) – vaccines: niche no longer

ESG, moving beyond the box tick

Oncology ABCs (part one) – a small-cap biopharma prospectus series

Cannabinoid manufacturing – Innovative approaches to the production of cannabinoids

Artificial intelligence in drug discovery

Biosynthesis – Taking the cannabinoid market to new heights

Confidence renewed as new COVID-19 vaccines demonstrate protection against emergent strains and efficacy with a single-dose regimen

Edison Exhibits- antibiotic development

The next wave in AMD

The A-B-T of biosimilars- Explaining contemporary life science issues

Cannabinoid Therapies- The coming retail wave

Cannabinoid Therapies- Therapeutics turning a corner

Trial outcomes and value – Explaining contemporary clinical trial issues

Drug pricing – Market access and reimbursement

The diagnostics sector

ASCO 2017

Deutsche Börse Eigenkapitalforum 2014 Research Guide

Edison healthcare quarterly: A boost for allergy immunotherapy

ASX Spotlight Conference – London, 6 March 2014

ASX Small to Mid Caps Conference – London, 7 March 2013

Edison healthcare quarterly: Boom times for US biotech

Edison healthcare quarterly: Crisis? What crisis?

Edison healthcare quarterly: How to please some of the people some of the time